1 / 15

Trends in Menopausal Hormone Therapy Use of U.S. Office-based Physicians, 2001-2008

Trends in Menopausal Hormone Therapy Use of U.S. Office-based Physicians, 2001-2008. SA Tsai MD, MPH, ML Stefanick, PhD, RS Stafford, MD, PhD Stanford Prevention Research Center NHLBI Training Session March 3, 2010. Introduction. WHI Estrogen + Progestin (E+P) 2002

tave
Download Presentation

Trends in Menopausal Hormone Therapy Use of U.S. Office-based Physicians, 2001-2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trends in Menopausal Hormone Therapy Use of U.S. Office-based Physicians, 2001-2008 SA Tsai MD, MPH, ML Stefanick, PhD, RS Stafford, MD, PhD Stanford Prevention Research Center NHLBI Training Session March 3, 2010

  2. Introduction • WHI Estrogen + Progestin (E+P) 2002 • Increased breast CA and CHD risk • MHT use declined • Practice recommendations changed • Not for use in CHD prevention • Use lowest effective dose • Use for shortest duration

  3. Additional Evidence • WHI ET 2004: more balanced risk-benefit profile • Sub-analyses: possible CV benefit younger women and closer to menopause • Low dose: similar benefits, dose response • Transdermal: lower venous thrombosis risk • Vaginal: less systemic absorption

  4. Objective • Evaluate whether MHT use was in line with recent evidence and current clinical recommendations • Examine if subgroups of women are using MHT in the expected ways

  5. Methods • National Disease and Therapeutic Index™ (NDTI) database, 2001-2008 • Physician survey • Selected from AMA/ AOA’s compiled list • 1800 physicians quarterly • Two consecutive randomly assigned workdays • Record patient diagnoses and meds • Info projected to national estimates

  6. Methods • Selected visits associated with MHT • Trends differentiated by: • Dose: • Standard (CEE 0.625mg or more) • Lower (CEE <0.625mg or estradiol 0.5 mg) • Route: • oral, transdermal, intramuscular, vaginal • Presence of progestin: ET or EPT • Patient age

  7. U.S. MHT Trends by Routes of Administration WHI E+P June 2002 WHI E alone April 2004

  8. Standard dose oral MHT use remains greater than Lower dose Prempro Low Premarin Low June 2003

  9. Total MHT Use

  10. Systemic MHT decreased most for oldest group Patient Visits in Thousands WHI E+P June 2002 WHI E alone April 2004 50-59 yo 60+ yo 59% <50 yo 66% 58% Year

  11. Lower dose oral MHT increased in all age groups Premarin Low, Prempro Low Approved June 2003 142% 46% 60+ yrs 206% 50-59 yrs <50 yrs

  12. Proportion of all oral MHT that is Lower dose increases over time

  13. Vaginal MHT use by age group 9% 60+ yo 71% 50-59 yo 26% <50 yo

  14. Conclusion • Continued slower MHT decline • Transformation of MHT - right direction • Lower dose - greater consideration • Transdermal may be underutilized • Greater recognition by patient age

  15. Thank you!

More Related